Autoantibodies in Achalasia
| Researcher | Population | Methods | Autoantibodies | Results |
|---|---|---|---|---|
| Goin et al,91 1999 | Chronic chagasic patients with achalasia (n = 19); without achalasia (n = 14); non-chagasic patients with idiopathic achalasia (n = 25); normal control (n = 20) | ELISA | Autoantibodies against M2 mAChR | There was a strong association between the existence of circulating anti-M2 mAChR antibodies and the presence of achalasia in chagasic patients. |
| Latiano et al,90 2006 | Achalasia (n = 41) | Indirect immunofluorescence; immunoblotting | Antineuronal antibodies | 10 of 41 (24.4%) patients presented antineuronal antibodies. |
| Control (n = 200) | ||||
| Kraichely et al,92 2010 | Achalasia (n = 70) | Radioimmunoprecipitation assays; ELISA; indirect immunofluorescence | GAD65 antibody | The overall prevalence of neural autoantibodies in achalasia was significantly higher, especially the GAD65 antibody (21.4%). |
| Control (n = 161) | ||||
| Mukaino et al,89 2018 | Achalasia (n = 28) | LIPS | Anti-gAChR antibodies | There is a significant prevalence of anti-gAChR antibodies in patients with Achalasia (21.4%). |
| CIPO l (n = 14) | ||||
| Priego-Ranero et al,93 2022 | Achalasia (n = 36) | Immune blot/line assay | Anti-GAD65 autoantibodies; | Most of the achalasia sera had anti-GAD65 (83%) and anti-PNMA2 (90%) autoantibodies. |
| Control (n = 22), EGJOO (n = 6); TD (n = 16) | Anti-PNMA2 autoantibodies |
ELISA, enzyme linked immunosorbent assay; M2 mAChR, M2-muscarinic acetylcholine receptors; GAD65, glutamic acid decarboxylase-65; CIPO, chronic intestinal pseudo-obstruction; LIPS, luciferase immunoprecipitation system assay; gAChR, ganglionic acetylcholine receptor; EGJOO, esophagogastric junction outflow obstruction; TD, transplant donors; PNMA2, paraneoplastic antigen Ma2.